Research programme: glutamate receptor modulators - Eli Lilly and Company
Alternative Names: GluR5 kainate receptor antagonists - Eli Lilly and Company; LY 503430; LY-2607540; LY-450108Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Isoquinolines
- Mechanism of Action AMPA receptor agonists; Kainic acid receptor antagonists; Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Mood disorders; Pain; Parkinson's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA